Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences wholesaler revenue concentration — Cencora, Inc. / AmerisourceBergen (% of total revenues) (%)
Form 10-K Note 2 Summary of Significant Accounting Policies
Latest, FY2025
2,100.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
2,100.0% in FY2024
History
5 years
Since FY2021
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Wholesaler revenue concentration — Cencora, Inc. / AmerisourceBergen (% of total revenues) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,100.0% | 0.0 pts | Form 10-K (filed 2026-02-24) ↗ |
| FY2024 | Dec 31, 2024 | 2,100.0% | -100.0 pts | Form 10-K (filed 2026-02-24) ↗ |
| FY2023 | Dec 31, 2023 | 2,200.0% | +400.0 pts | Form 10-K (filed 2026-02-24) ↗ |
| FY2022 | Dec 31, 2022 | 1,800.0% | -500.0 pts | Form 10-K (filed 2025-02-28) ↗ |
| FY2021 | Dec 31, 2021 | 2,300.0% | – | Form 10-K (filed 2024-02-23) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Wholesaler revenue concentration — Cencora, Inc. / AmerisourceBergen (% of total revenues) (%), annual FY2021–FY2025 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/conc_cencora_rev
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.